🇺🇸 FDA
Pipeline program

cemiplimab (monotherapy)

R2810-ONC-1690

Phase 2 small_molecule terminated

Quick answer

cemiplimab (monotherapy) for Relapsed Solid Tumor is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Relapsed Solid Tumor
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials